Carl Danzig, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the 72-Week results from the Phase 3 BALATON and COMINO trials at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
Srinivas Sai Kondapalli, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the predictive role of outer retinal tubulations in lesion growth for subfoveal and non subfoveal geographic atrophy at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
Scott Xiao, co-founder and CEO of Luminopia, sat with Ophthalmology Times to discuss the PUPiL Registry and how the VR treatment for children with amblyopia works and can revolutionize amblyopia treatment.
6E10 combined with local prophylaxishas been selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks.
Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, spoke with attendees, who shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.
Attendees shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.
4D-150 Is being evaluated in wet age-related macular degeneration (AMD).
Jennifer Lim, MD, FARVO, FASRS, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on differential artery-vein analysis in eyes with diabetic retinopathy and improvements on the OCTA classification using artificial intelligence at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
The key factor may be the control of inflammation.
The company’s Spectralis OCTA module with SHIFT technology offers a tool for the diagnoses and management of retinal diseases.
Scientists from the International Centre from Translational Eye Research used multiwavelength laser Doppler holography to assess blood flow in various layers of the human retina in vivo, which may impact the diagnosis of circulatory disorders.
This marks 21 years in a row the hospital has been top-ranked by the US News & World Report in the field of ophthalmology.
Investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata
Claes H. Dohlman, MD, PhD, has been recognized globally as the founding father of modern corneal science, He was instrumental in driving research investigations to help better understand the structure and function of the cornea.
EyeBio is developing a pipeline of clinical and preclinical candidates for the prevention and treatment of vision loss associated with retinal vascular leakage.
Researchers from the UKB Eye Clinic, in cooperation with the University of Bonn and in close collaboration with basic and clinical scientists, have examined patients with early forms of AMD. The researchers focused on the so-called iRORA lesions, which are very early anatomical signs of retinal damage.
The approach to treating amblyopia in young children couples proprietary therapeutic software with virtual reality (VR) headsets and popular children's TV shows
Researchers, led by Shigemi Matsuyama, PhD, will conduct research seeking a potential breakthrough drug that can be taken orally—one that may address many RP disease manifestations, regardless of the underlying genetic mutation.
AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.
Ophthalmologists were able to remove the stinger after identifying its location during a slit lamp examination.
Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss nonleaking cystoid macular edema and subretinal fluid out of proportion to optic disc edema in idiopathic intracranial hypertension in the setting of optic atrophy.
The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.
A novel formulation may prevent blood vessel growth and vascular leakage in the retina.
The companies are teaming up to reduce care gaps and improve eye and vision health by bringing diabetic retinopathy and other eye disease screening services to patients in their own homes and workplaces.
A team of researchers at the Ohio State University found that in mice an enzyme related to cell growth and division is a culprit in the blood vessel invasion in the back of the eye that causes blurred central vision in wet AMD.
Ophthalmologist receives the Roger Steinert, MD, Legacy Award during the Octane Ophthalmology Tech Forum in Irvine, California.
According to the company, FYSX is the first non-pharmacological, non-surgical treatment designed to lower IOP for glaucoma patients.
Prescriptions with semaglutide (Wegovy, Ozempic, Novo Nordisk) are FDA approved to treat obesity and type 2 diabetes, respectively.
Chris Brittain, vice president, Global Head of Ophthalmology Product Development at Genentech, sat with Ophthalmology Times to discuss the company's plans with Susvimo following the FDA approval for relaunch.
The company announced it has received FDA approval to relaunch Susvimo for intravitreal use via an ocular implant for treating people with wet AMD.
